Appclon Registers US Patent for CAR-T Therapy 'AT101'

[Asia Economy Reporter Lee Gwanju] Appclon announced on the 9th that the U.S. patent registration for the CAR-T cell therapy 'AT101' has been approved.

The patent registered this time by Appclon is for a CAR-T therapy using the h1218 antibody, which has been applied to the company's core pipeline, AT101. This patent is registered not only in the U.S. but also in Korea, Japan, and Canada, and is currently under review in Europe and China.

Among the four globally approved CD19-targeting CAR-T therapies for hematologic cancers (Kymriah, Yescarta, Tecartus, Breyanzi), all commonly use the mouse-derived FMC63 antibody. However, Appclon's therapy uses the h1218 humanized antibody, recognized as proprietary technology through patent registration.

The h1218 antibody binds to a new epitope of the CD19 disease protein. Appclon expects that AT101 will not only demonstrate differentiated therapeutic effects against hematologic cancers compared to existing therapies but also maintain CAR-T activity for an extended period due to the application of humanized antibody technology.

An Appclon representative stated, "With the acquisition of the U.S. patent, we will secure the technological competitiveness of AT101 in major markets, which will accelerate global commercialization and overseas technology transfer."

AT101 is currently undergoing a Phase 1 clinical trial in Korea at four hospitals, including Seoul Asan Medical Center, supported by the National New Drug Development Project.

This content was produced with the assistance of AI translation services.